Develops phage therapies targeting specific bacterial pathogens associated with chronic diseases.
BiomX Inc., headquartered in Ness Ziona, Israel, is a pioneering clinical-stage microbiome company focused on harnessing natural and engineered phage technologies to combat specific harmful bacteria. Established in 2015, BiomX is dedicated to developing innovative products that target bacteria impacting both skin appearance and chronic diseases such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
At the forefront of BiomX's pipeline is BX004, a phage therapy designed for CF patients suffering from chronic Pseudomonas aeruginosa respiratory infections, currently undergoing Phase 1b/2a clinical trials. The company's robust portfolio also includes BX005, a topical phage cocktail targeting Staphylococcus aureus (S. aureus), a bacteria associated with various skin conditions, advancing through Phase 1/2 clinical studies. Additionally, BiomX is developing BX003, an orally administered phage cocktail in Phase 1b/2a trials, targeting bacterial strains prevalent in the gut microbiomes of IBD and PSC patients.
BiomX further extends its impact in oncology with a colorectal cancer program utilizing engineered phage therapies. These therapies, administered intravenously, specifically target Fusobacterium nucleatum bacteria within the tumor microenvironment. Through strategic research and development initiatives, BiomX aims to revolutionize microbiome-based therapies, offering new hope for patients suffering from challenging bacterial infections and chronic diseases worldwide.